103 related articles for article (PubMed ID: 10233785)
1. Severe heart failure: balancing length and quality of life.
Harv Heart Lett; 1999 Jun; 9(10):1-2. PubMed ID: 10233785
[No Abstract] [Full Text] [Related]
2. Chronic heart failure and the quality of life.
Pritzker MR
N Engl J Med; 1999 May; 340(19):1511; author reply 1512. PubMed ID: 10328720
[No Abstract] [Full Text] [Related]
3. Vesnarinone for heart failure.
Neely D
N Engl J Med; 1994 Jan; 330(1):65. PubMed ID: 8259152
[No Abstract] [Full Text] [Related]
4. Inotropic therapy for heart failure.
Stevenson LW
N Engl J Med; 1998 Dec; 339(25):1848-50. PubMed ID: 9854124
[No Abstract] [Full Text] [Related]
5. [Usefulness of OPC-8212, an inotropic agent, in patients with chronic congestive heart failure--a multiple dose evaluation on its effect and arrhythmogenesis].
Fukuda K; Handa S; Ogawa S; Nakamura Y; Kawamura Y
Kokyu To Junkan; 1988 Oct; 36(10):1125-31. PubMed ID: 3247528
[No Abstract] [Full Text] [Related]
6. Chronic heart failure and the quality of life.
Alhaddad IA
N Engl J Med; 1999 May; 340(19):1511-2. PubMed ID: 10328721
[No Abstract] [Full Text] [Related]
7. Intravenous amrinone for congestive heart failure.
Med Lett Drugs Ther; 1984 Nov; 26(675):104-5. PubMed ID: 6390109
[No Abstract] [Full Text] [Related]
8. Predictors of clinical outcome in advanced heart failure patients on continuous intravenous milrinone therapy.
Bhat G
ASAIO J; 2006; 52(6):677-81. PubMed ID: 17117058
[TBL] [Abstract][Full Text] [Related]
9. Positive inotropic agents: a double-edged sword for chronic heart failure.
Asanoi H; Inoue H
Intern Med; 1996 Jan; 35(1):63-4. PubMed ID: 8652942
[No Abstract] [Full Text] [Related]
10. Vesnarinone for heart failure.
Schwartz A; Grupp I; Grupp G
N Engl J Med; 1994 Jan; 330(1):65; author reply 66. PubMed ID: 8259153
[No Abstract] [Full Text] [Related]
11. Vesnarinone for heart failure.
Swedberg K; Wedel H
N Engl J Med; 1994 Jan; 330(1):64; author reply 65. PubMed ID: 8259151
[No Abstract] [Full Text] [Related]
12. A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advanced heart failure.
Loh E; Elkayam U; Cody R; Bristow M; Jaski B; Colucci WS
J Card Fail; 2001 Jun; 7(2):114-21. PubMed ID: 11420762
[TBL] [Abstract][Full Text] [Related]
13. [Challenge for the general practitioner. Sufficient therapy for heart failure].
Füessl HS
MMW Fortschr Med; 2000 Nov; 142(46):4-8. PubMed ID: 11132311
[No Abstract] [Full Text] [Related]
14. [Intravenous milrinone in the treatment of pediatric heart failure].
Han XZ; Sun Y
Zhongguo Dang Dai Er Ke Za Zhi; 2007 Feb; 9(1):73-4. PubMed ID: 17306085
[No Abstract] [Full Text] [Related]
15. Pharmacy Support of a Pediatric Patient Receiving Milrinone at Home.
Xue A; Dersch-Mills D; Tsang C; Greenway SC
Can J Hosp Pharm; 2016; 69(5):415-419. PubMed ID: 27826160
[No Abstract] [Full Text] [Related]
16. The search for the ideal positive inotropic agent.
Packer M
N Engl J Med; 1993 Jul; 329(3):201-2. PubMed ID: 8515793
[No Abstract] [Full Text] [Related]
17. Present status of various inotropic agents in heart failure.
Mittal SR; Maheshwari N
J Assoc Physicians India; 2001 Nov; 49():1095-9. PubMed ID: 11868865
[No Abstract] [Full Text] [Related]
18. Review of a dose-dependent increase in mortality with vesnarinone among patients with severe heart failure.
LeJemtel TH
Curr Cardiol Rep; 1999 May; 1(1):31. PubMed ID: 10980817
[No Abstract] [Full Text] [Related]
19. [Inotropic agents in advanced and refractory heart failure].
Mangiavacchi M; Gronda E
Ital Heart J Suppl; 2003 Jan; 4(1):3-7. PubMed ID: 12690928
[No Abstract] [Full Text] [Related]
20. Dangers of amrinone.
Kark P; Gillmer DJ
S Afr Med J; 1984 Jul; 66(1):6. PubMed ID: 6729657
[No Abstract] [Full Text] [Related]
[Next] [New Search]
